Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

simtuzumab

- PMLiVE

US senators seeks answers on Sovaldi pricing

Gilead asked to justify pricing of hepatitis drug

The seven letter debate that is Sovaldi

Reimbursement of high cost hepatitis C drugs raise difficult issues

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

- PMLiVE

SMC: Celgene’s Abraxane ‘too expensive’ for Scotland

But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta

- PMLiVE

Halozyme to resume pancreatic cancer study

FDA says PEGPH20 trial can continue

- PMLiVE

Halozyme halts pancreatic cancer trial

The biopharma company is investigating PEGPH20’s links to blood clot

- PMLiVE

Global pancreatic cancer market to treble in value

Celgene's Abraxane will drive rapid growth over next three years

- PMLiVE

Gilead taken to task over Sovaldi pricing

US politicians question high cost of new hepatitis C drug

- PMLiVE

Pancreatic cancer campaign prompts backlash

Charity’s marketing featured people saying they wished they had another form of cancer

- PMLiVE

EU clears Gilead’s hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus

- PMLiVE

Celgene wins EU pancreatic cancer approval for Abraxane

Adds to drug's existing breast cancer indication

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links